Baugh & Associates LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 0.3% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 114,240 shares of the biopharmaceutical company’s stock after selling 355 shares during the quarter. Pfizer comprises 3.5% of Baugh & Associates LLC’s portfolio, making the stock its 11th largest holding. Baugh & Associates LLC’s holdings in Pfizer were worth $5,914,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently made changes to their positions in the business. Norges Bank acquired a new position in shares of Pfizer during the fourth quarter worth approximately $3,351,891,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in shares of Pfizer by 577.8% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,247,903 shares of the biopharmaceutical company’s stock worth $715,270,000 after buying an additional 10,440,786 shares during the last quarter. Coatue Management LLC acquired a new position in shares of Pfizer during the fourth quarter worth approximately $608,919,000. Darwin Global Management Ltd. acquired a new position in shares of Pfizer during the fourth quarter worth approximately $454,553,000. Finally, State Street Corp lifted its holdings in shares of Pfizer by 1.8% during the fourth quarter. State Street Corp now owns 284,816,832 shares of the biopharmaceutical company’s stock worth $16,818,434,000 after buying an additional 5,013,651 shares during the last quarter. 66.50% of the stock is owned by hedge funds and other institutional investors.
In related news, SVP Jennifer B. Damico sold 4,218 shares of the firm’s stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $53.96, for a total value of $227,603.28. Following the transaction, the senior vice president now owns 10,846 shares in the company, valued at $585,250.16. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of the firm’s stock in a transaction dated Thursday, May 12th. The shares were sold at an average price of $50.00, for a total value of $1,645,400.00. Following the completion of the transaction, the executive vice president now owns 38,146 shares in the company, valued at approximately $1,907,300. The disclosure for this sale can be found here. In the last quarter, insiders sold 41,126 shares of company stock worth $2,075,003. 0.05% of the stock is owned by company insiders.
Shares of PFE stock opened at $52.31 on Friday. The stock’s fifty day moving average is $50.66 and its 200-day moving average is $52.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39. The stock has a market capitalization of $293.51 billion, a PE ratio of 12.00, a PEG ratio of 0.63 and a beta of 0.76. Pfizer Inc. has a 52 week low of $38.93 and a 52 week high of $61.71.
Pfizer (NYSE:PFE – Get Rating) last announced its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 EPS for the quarter, missing the consensus estimate of $1.66 by ($0.04). The business had revenue of $25.66 billion for the quarter, compared to the consensus estimate of $24.73 billion. Pfizer had a return on equity of 38.29% and a net margin of 26.97%. Pfizer’s revenue for the quarter was up 76.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.93 EPS. As a group, analysts forecast that Pfizer Inc. will post 6.61 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Wednesday, June 29th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 3.06%. The ex-dividend date of this dividend is Thursday, July 28th. Pfizer’s dividend payout ratio is 36.70%.
A number of research analysts recently commented on PFE shares. Barclays set a $52.00 target price on Pfizer in a research note on Monday, June 27th. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 19th. Morgan Stanley started coverage on Pfizer in a research note on Wednesday, April 6th. They issued an “equal weight” rating and a $55.00 target price for the company. The Goldman Sachs Group set a $51.00 target price on Pfizer in a research note on Wednesday, May 25th. Finally, Wells Fargo & Company cut their target price on Pfizer from $60.00 to $55.00 in a research note on Wednesday, May 4th. Nine equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $57.26.
Pfizer Company Profile (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.